Document is current
Any future updates will be listed below
-
Authors
Ansell, Stephen M. https://orcid.org/0000-0003-1244-6758
Nowakowski, Grzegorz S. https://orcid.org/0000-0002-6955-9393
- License Information
-
More Information
Article History
Received: 15 September 2025
Revised: 20 January 2026
Accepted: 25 February 2026
First Online: 10 March 2026
Competing interests
: SMA—Receives research funding for clinical trials from Takeda, Bristol Myers Squibb, Pfizer, AstraZeneca, Affimed, StepPharma, ADC Therapeutics, and Regeneron. GSN—Has a consulting or advisory role for Celgene, MorphoSys, Genentech, Selvita, Debiopharm Group, Kite/ Gilead, TG Therapeutics, Kymera, Karyopharm Therapeutics, Ryvu Therapeutics, Bantam Pharmaceutical, Bristol Myers Squibb/Celgene, AbbVie, Genmab, Roche Pharma AG; and receives research funding from Celgene, NanoString Technologies, and MorphoSys.
